Table 4.
Outcomes in men with very-high-risk disease and other NCCN high-risk men undergoing definitive radiation and radical prostatectomy*
| VHR | Other NCCN high-risk | |||
|---|---|---|---|---|
| Definitive RT | RP | Definitive RT | RP | |
| 10-year BFFS†, % | 37.3 (22.8–51.3) | 20.6 (9.0–35.6) | 55.2 (41.9–66.6) | 41.2 (36.0–46.2) |
| 10-year MFS, % | 58.7 (44.9–70.3) | 36.9 (19.8–54.2) | 83.8 (75.3–89.6) | 77.9 (72.2–82.6) |
| 10-year PCSS, % | 79.4 (69.2–86.6) | 62.2 (44.7–75.5) | 93.4 (88.4–96.3) | 89.5 (85.0–92.8) |
| 10-year OS, % | 63.6 (53.0–72.4) | 57.9 (41.6–71.1) | 73.0 (65.8–78.9) | 83.3 (78.2–87.2) |
Outcomes for RP cohort were previously published (Sundi D, Wang VM, Pierorazio PM, et al. Very-high-risk localized prostate cancer: definition and outcomes. Prostate Cancer and Prostatic Dis. 2014;17(1):57–63) and had been analyzed using Kaplan-Meier methods and life tables. For the purpose of consistency, we re-analyzed our data using similar methods, which is summarized above.
For patients undergoing definitive radiation, biochemical failure-free survival was defined in accordance with the Radiation Therapy Oncology Group – Association of Therapeutic Radiation Oncology Phoenix Consensus Conference definition.13 For patients undergoing radical prostatectomy, biochemical failure was defined as a post-operative increase in PSA (2 ng/mL)
Abbreviations: very-high-risk (VHR); radiation therapy (RT); radical prostatectomy (RP); biochemical failure-free survival (BFFS); metastasis-free survival (MFS); prostate cancer-specific survival (PCSS); overall survival (OS)